Springworks Therapeutics Stock Analysis
| SWTX Stock | USD 39.39 0.37 0.95% |
SpringWorks Therapeutics is undervalued with Real Value of 43.63 and Target Price of 50.17. The main objective of SpringWorks Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what SpringWorks Therapeutics is worth, separate from its market price. There are two main types of SpringWorks Therapeutics' stock analysis: fundamental analysis and technical analysis.
The SpringWorks Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. SpringWorks Therapeutics is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. SpringWorks Stock trading window is adjusted to America/New York timezone.
SpringWorks |
SpringWorks Stock Analysis Notes
About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.89. SpringWorks Therapeutics had not issued any dividends in recent years. SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. Springworks Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people. To find out more about SpringWorks Therapeutics contact Saqib JD at 203 883 9490 or learn more at https://www.springworkstx.com.SpringWorks Therapeutics Investment Alerts
| SpringWorks Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 5.45 M. Net Loss for the year was (325.1 M) with profit before overhead, payroll, taxes, and interest of 35 M. | |
| SpringWorks Therapeutics currently holds about 334.54 M in cash with (222.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.81. | |
| SpringWorks Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: SpringWorks Therapeutics SWOT analysis stock shows promise amid challenges |
SpringWorks Therapeutics Upcoming and Recent Events
Earnings reports are used by SpringWorks Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
SpringWorks Largest EPS Surprises
Earnings surprises can significantly impact SpringWorks Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-04 | 2021-09-30 | -0.76 | -0.84 | -0.08 | 10 | ||
2021-05-05 | 2021-03-31 | -0.51 | -0.62 | -0.11 | 21 | ||
2020-08-12 | 2020-06-30 | -0.36 | -0.47 | -0.11 | 30 |
SpringWorks Therapeutics Environmental, Social, and Governance (ESG) Scores
SpringWorks Therapeutics' ESG score is a quantitative measure that evaluates SpringWorks Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of SpringWorks Therapeutics' operations that may have significant financial implications and affect SpringWorks Therapeutics' stock price as well as guide investors towards more socially responsible investments.
SpringWorks Stock Institutional Investors
| Shares | Pictet Asset Manangement Sa | 2024-06-30 | 1.6 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 1.5 M | Woodline Partners Lp | 2024-06-30 | 1.4 M | Artal Group S A | 2024-06-30 | 1.3 M | Fiera Capital Corporation | 2024-06-30 | 1.3 M | Capital Research & Mgmt Co - Division 3 | 2024-09-30 | 1.2 M | Lord, Abbett & Co Llc | 2024-09-30 | 1.1 M | Polar Capital Holdings Plc | 2024-06-30 | 1000 K | Gw&k Investment Management, Llc | 2024-09-30 | 925.4 K | Fmr Inc | 2024-09-30 | 11.1 M | Vanguard Group Inc | 2024-09-30 | 6.7 M |
SpringWorks Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.93 B.SpringWorks Profitablity
The company has Profit Margin (PM) of (2.03) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.18) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.18.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.45) | (0.48) | |
| Return On Capital Employed | (0.53) | (0.56) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (0.52) | (0.49) |
Management Efficiency
SpringWorks Therapeutics has return on total asset (ROA) of (0.3428) % which means that it has lost $0.3428 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5933) %, meaning that it created substantial loss on money invested by shareholders. SpringWorks Therapeutics' management efficiency ratios could be used to measure how well SpringWorks Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.48 in 2024. Return On Capital Employed is likely to drop to -0.56 in 2024. At this time, SpringWorks Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 13.3 M in 2024, whereas Other Assets are likely to drop slightly above 2.2 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.92 | 5.54 | |
| Tangible Book Value Per Share | 9.74 | 5.53 | |
| Enterprise Value Over EBITDA | (6.25) | (6.57) | |
| Price Book Value Ratio | 3.68 | 3.86 | |
| Enterprise Value Multiple | (6.25) | (6.57) | |
| Price Fair Value | 3.68 | 3.86 | |
| Enterprise Value | 1.2 B | 1.3 B |
Understanding the operational decisions made by SpringWorks Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Operating Margin (1.18) | Profit Margin (2.03) | Beta 0.792 | Return On Assets (0.34) | Return On Equity (0.59) |
Technical Drivers
As of the 26th of November, SpringWorks Therapeutics has the Risk Adjusted Performance of 0.001, coefficient of variation of (11,958), and Variance of 8.55. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of SpringWorks Therapeutics, as well as the relationship between them.SpringWorks Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. SpringWorks Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for SpringWorks Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
SpringWorks Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific SpringWorks Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on SpringWorks Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases SpringWorks Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
SpringWorks Therapeutics Outstanding Bonds
SpringWorks Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. SpringWorks Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most SpringWorks bonds can be classified according to their maturity, which is the date when SpringWorks Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| SPIRIT AEROSYSTEMS INC Corp BondUS85205TAG58 | View | |
| SPR 9375 30 NOV 29 Corp BondUS85205TAN00 | View | |
| SPIRIT AEROSYSTEMS INC Corp BondUS85205TAK60 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| SPRINT P 7625 Corp BondUS85207UAK16 | View | |
| Sprint 7625 percent Corp BondUS85207UAJ43 | View | |
| SPRINT NEXTEL P Corp BondUS85208NAE04 | View |
SpringWorks Therapeutics Predictive Daily Indicators
SpringWorks Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of SpringWorks Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
SpringWorks Therapeutics Corporate Filings
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 25th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 3rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 4th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 3rd of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 7th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 30th of July 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
SpringWorks Therapeutics Forecast Models
SpringWorks Therapeutics' time-series forecasting models are one of many SpringWorks Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary SpringWorks Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About SpringWorks Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how SpringWorks Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling SpringWorks shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as SpringWorks Therapeutics. By using and applying SpringWorks Stock analysis, traders can create a robust methodology for identifying SpringWorks entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (59.68) | (62.67) | |
| Operating Profit Margin | (62.97) | (66.12) | |
| Net Loss | (59.68) | (62.67) | |
| Gross Profit Margin | 0.92 | 0.96 |
Current SpringWorks Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. SpringWorks analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. SpringWorks analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 50.17 | Strong Buy | 9 | Odds |
Most SpringWorks analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand SpringWorks stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of SpringWorks Therapeutics, talking to its executives and customers, or listening to SpringWorks conference calls.
SpringWorks Stock Analysis Indicators
SpringWorks Therapeutics stock analysis indicators help investors evaluate how SpringWorks Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading SpringWorks Therapeutics shares will generate the highest return on investment. By understating and applying SpringWorks Therapeutics stock analysis, traders can identify SpringWorks Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 68.1 M | |
| Common Stock Shares Outstanding | 63.1 M | |
| Total Stockholder Equity | 626.2 M | |
| Property Plant And Equipment Net | 24.1 M | |
| Cash And Short Term Investments | 479.2 M | |
| Cash | 176.1 M | |
| Accounts Payable | 7.4 M | |
| Net Debt | -169 M | |
| 50 Day M A | 32.6047 | |
| Total Current Liabilities | 78.2 M | |
| Other Operating Expenses | 348.5 M | |
| Non Current Assets Total | 224.9 M | |
| Forward Price Earnings | 322.5806 | |
| Non Currrent Assets Other | 4.2 M | |
| Stock Based Compensation | 94.5 M |
Additional Tools for SpringWorks Stock Analysis
When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.